University of California, San Diego Performance-Based Skills Assessment

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Wednesday, November 8, 2023

For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.

Key Points: 
  • For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.
  • Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, November 1-5, 2023, San Diego, CA
    In November 2023, Tango scientists presented preclinical data highlighting the potential of TNG260 in STK11-mutant cancers.
  • AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11-15, 2023, Boston, MA
    In October 2023, Tango scientists presented five posters highlighting preclinical data from the precision oncology pipeline and synthetic lethality discovery platform.
  • The year-to-date increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta

Retrieved on: 
Thursday, November 2, 2023

Glaucoma is an age-related neurodegenerative disease associated with the loss of retinal ganglion cells and characteristic vision loss.

Key Points: 
  • Glaucoma is an age-related neurodegenerative disease associated with the loss of retinal ganglion cells and characteristic vision loss.
  • Converging data indicate that amyloid beta, best known for its association with Alzheimer’s disease, is a key factor in glaucoma pathogenesis.
  • In collaboration with the University of California-San Diego (UCSD), Amydis completed critical proof-of-concept studies demonstrating the Amydis tracers detect amyloid beta in post-mortem human eyes of glaucoma patients, but not healthy subjects.
  • This multi-modal data will include optical coherence tomography (OCT) and OCT Angiography (OCT-A), enabling Amydis to map retinal amyloid beta, retinal structure (OCT), and retinal vascular (OCT-A) signatures and monitor their relative changes to better understand the pathophysiology of glaucoma.

New Physician Guidelines Recommend Contrast Enhanced Ultrasound to Diagnose Certain Liver Cancers

Retrieved on: 
Tuesday, October 3, 2023

New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer.

Key Points: 
  • New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer.
  • The new guidelines recommend CEUS for diagnosing HCC when MR and CT are inconclusive, unavailable or contraindicated.
  • CEUS uses FDA-approved “microbubble” ultrasound contrast agents (UCAs) that are administered intravenously during an ultrasound scan.
  • UCAs are manufactured and sold in the US and elsewhere by Bracco, Lantheus and GE Healthcare.

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Retrieved on: 
Thursday, September 28, 2023

Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD.

Key Points: 
  • Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD.
  • “We are excited about the results of the ATTUNE trial that delivered a positive dataset with treatment effects considerably higher than currently approved therapies.
  • Despite the clinical heterogeneity of PTSD, the results of ATTUNE demonstrated broad benefits with BNC210 across a number of symptoms.
  • The company will discuss the topline ATTUNE study results on the webcast today at 8:00am EST and is planning to advance BNC210 for the treatment of PTSD into registrational studies.

Nanoscope Therapeutics Strengthens Clinical and Regulatory Expertise With Appointment of Samuel Barone, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, September 21, 2023

The regulatory expertise garnered during his tenure at the FDA will be instrumental as we continue to advance our pipeline through late-stage clinical development and navigate the regulatory process," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope.

Key Points: 
  • The regulatory expertise garnered during his tenure at the FDA will be instrumental as we continue to advance our pipeline through late-stage clinical development and navigate the regulatory process," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope.
  • "Dr. Barone will support our mission to bring sight-restoring therapies to patients with inherited retinal diseases in an expeditious manner."
  • Prior to that he was Chief Medical Officer for Veloce BioPharma, a topical therapeutics company focusing on unmet clinical needs in dermatology, ophthalmology and supportive oncology.
  • He was also Chief Medical Officer for Avalanche Biotechnologies and then Senior Vice President, Clinical Development, for Adverum Biotechnologies.

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

Retrieved on: 
Friday, September 15, 2023

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer.
  • “Minnie is an accomplished biopharmaceutical leader who brings extensive clinical development and cross-functional portfolio management experience to Pliant,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer at Pliant.
  • Prior to joining Pliant, Ms. Kuo held roles of increasing responsibilities at Vir Biotechnology, most recently serving as Senior Vice President of Translational and Clinical Development Operations.
  • In this role, Ms. Kuo served as the operational officer to the Chief Medical Officer, overseeing business operations, clinical operations, and organizational planning across the entire clinical portfolio.

Learn the Facts About Interstitial Lung Disease on ILD Day, Sept. 13

Retrieved on: 
Thursday, August 31, 2023

CHICAGO, Aug. 31, 2023 /PRNewswire/ -- With more than 250,000 Americans living with interstitial lung disease (ILD) and pulmonary fibrosis (PF), nine organizations are joining forces to present the third annual ILD Day on Wednesday, Sept. 13, to drive awareness of the diseases.

Key Points: 
  • CHICAGO, Aug. 31, 2023 /PRNewswire/ -- With more than 250,000 Americans living with interstitial lung disease (ILD) and pulmonary fibrosis (PF), nine organizations are joining forces to present the third annual ILD Day on Wednesday, Sept. 13, to drive awareness of the diseases.
  • Pulmonary fibrosis can be seen in many types of ILD and the damage caused by ILD can be irreversible and worsen over time.
  • "Since the symptoms of ILD are similar to other more common illnesses, it can be difficult to diagnose.
  • To register for the ILD Day webinar or for more information about ILD, visit ILDDay.org .

Acne bacteria trigger cells to produce fats, oils and other lipids essential to skin health – new research

Retrieved on: 
Wednesday, August 23, 2023

And despite the misconception that lipids harm your skin by causing oiliness and acne, they actually play a vital role in maintaining the skin barrier.

Key Points: 
  • And despite the misconception that lipids harm your skin by causing oiliness and acne, they actually play a vital role in maintaining the skin barrier.
  • Lipids – organic compounds that include fats, oils, waxes and other types of molecules – are essential components of the outermost layer of skin.
  • For example, by increasing the lipid content in skin cells, propionic acid reduced water loss through the skin.
  • We also found that the lipids skin cells produce after exposure to C. acnes or propionic acid have antimicrobial effects against C. acnes.

Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter ended June 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter ended June 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.
  • “The Lineage team continued to execute across multiple fronts during the second quarter, advancing our clinical and preclinical cell transplant programs and supporting our valuable alliances,” stated Brian M. Culley, Lineage CEO.
  • We also reported positive clinical results from a Phase 1 study of VAC2 in non-small cell lung cancer alongside our partner, Cancer Research UK.
  • Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.

Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Thursday, August 10, 2023

“The second quarter of 2023 marked a period of strong forward momentum across our cardiovascular AAV and hematology LV portfolios highlighted by the BLA submission for our LAD-I program, Rocket’s first product filing.

Key Points: 
  • “The second quarter of 2023 marked a period of strong forward momentum across our cardiovascular AAV and hematology LV portfolios highlighted by the BLA submission for our LAD-I program, Rocket’s first product filing.
  • ATMP designation is intended for medicines that offer groundbreaking new opportunities and allows for a single evaluation and authorization procedure.
  • Initiating two-patient pediatric safety run-in for RP-A501 pivotal study; approaching final alignment with FDA on primary composite endpoint to support accelerated approval.
  • As of June 30, 2023, Rocket had cash, cash equivalents and investments of $307.0 million.